Hatteras Venture Partners

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

BEKhealth is a clinical research software company that utilizes an AI-powered platform to enhance the efficiency of clinical trials and observational studies. By automating various processes, BEKhealth enables organizations to better understand their patient populations, optimize feasibility, and speed up site selection. The platform extracts and processes both structured and unstructured data from electronic medical records, allowing for a more comprehensive understanding of trial eligibility criteria. This capability leads to the identification of significantly more protocol-eligible candidates, resulting in a tenfold increase in qualified patients and halving the enrollment timeline. Through its innovative approach, BEKhealth aims to reduce costs and streamline the overall clinical research process for its clients.

Synaptrix specializes in developing innovative, non-opioid pain management solutions. The company focuses on creating medical devices that employ neuromodulation technology, using electrical or chemical stimulation to alleviate postoperative pain without compromising motor function or touch. This approach aims to provide healthcare professionals with effective, long-lasting alternatives to opioids, promoting rehabilitation and reducing the need for these medications.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

iVEAcare specializes in developing advanced neuromodulation therapies to address unmet clinical needs, focusing on chronic diseases. The company creates innovative devices and software that deliver targeted electrical stimulation to specific areas of the brain or spinal cord, aiming to enhance treatment effectiveness and reduce invasiveness.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Aer Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for respiratory diseases characterized by excess mucus and mucus plugs. Its primary focus lies in addressing significant unmet needs in conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma.

Mercy BioAnalytics is a biotechnology company dedicated to improving and saving lives through early cancer detection. Founded in 2018, it has developed a proprietary platform that uses extracellular vesicles (EVs) in blood to detect stage I cancer.

Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Boomerang Medical is a female-led bioelectronic medical technology company developing bioelectric neuromodulation therapies to treat autoimmune diseases. The company aims to advance treatment for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis by leveraging bioelectronic medicine to modulate neural pathways involved in immune responses, with the goal of offering more effective and targeted therapies. The approach has drawn regulatory attention, having received FDA breakthrough device designation for Crohn's disease and ulcerative colitis, signaling potential for improved patient outcomes.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Founded in 2012, Wildflower Health is a San Francisco-based company that specializes in smartphone-based health programs. It offers Due Date Plus for maternity care and GROW for family health, providing services such as reminders, provider look-up, and health risk assessments to support users and connect them with healthcare providers.

Huma.AI provides an AI-powered knowledge automation platform for the healthcare and life sciences sectors. The platform connects disparate data silos by enabling natural-language queries to surface answers, insights, and actions from unstructured data such as documents and free text. By linking systems through human language, it helps researchers, clinicians, and organizations access data more quickly and make data-informed decisions. Huma.AI's solution is designed to improve efficiency in pharmaceutical and health care workflows by extracting insights from diverse data sources and presenting them in actionable form. The company was founded in 2016 and is based in Palo Alto, California.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

Tune Therapeutics develops cell and gene therapies guided by epigenetic programming to treat devastating diseases. The company is building an epigenetic programming platform that enables new pathways for disease treatment by tapping into the epigenome to program biology without altering the DNA sequence. This approach aims to deliver paradigm-changing therapies by modulating gene expression through epigenetic mechanisms rather than editing the genome, expanding options for diseases where conventional treatments have limited efficacy. By integrating epigenetics and cell biology, the company seeks durable, precise interventions that can reprogram cellular states to restore function while minimizing genetic change. The emphasis is on research and development to advance candidates toward clinical use to address severe and unmet medical needs.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

GoCheck, formerly known as Gobiquity, Inc., is a technology company based in Aliso Viejo, California, that specializes in mobile health applications aimed at the early detection and prevention of eye diseases in children. The company's flagship product, GoCheck Kids, is a smartphone app designed for the screening of amblyopia risk factors, adhering to guidelines established by the American Association for Pediatric Ophthalmology and Strabismus. With a focus on affordability, GoCheck Kids reduces the cost of vision screening by over 60% by utilizing the manufacturing capabilities of smartphones. The app is FDA-registered and CE certified, and it is currently utilized by over 6,500 pediatric teams across the U.S. and Europe. By facilitating early detection, GoCheck aims to combat vision impairment, a leading disabling condition among children, which can severely impact learning and overall health outcomes.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing therapeutics that restore the function of microglia, the brain's immune cells. The company aims to improve outcomes for patients with neurodegenerative diseases by advancing its lead monoclonal antibody TREM2 agonist through Phase 1 trials and progressing its small molecule TREM2 agonist towards an Investigational New Drug (IND) application.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, specializing in the development of surgical instruments for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. Founded in 2014, the company has created a series of disposable surgical tools designed to work alongside general-use endoscopic staplers. These innovative tools help surgeons standardize their techniques, reduce variability, and minimize waste during procedures. By decreasing the number of cartridges needed for each surgery, Standard Bariatrics enables healthcare providers to lower costs while ensuring consistent surgical outcomes.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

NoviSci is a software analytics and services company focused on enhancing population health outcomes, particularly for vulnerable patients with complex health conditions. The company leverages advanced data science techniques to visualize and analyze health data, employing modern epidemiological methods grounded in sound scientific principles. Through its innovative tools, NoviSci aims to improve the health and well-being of individuals by providing insights that drive better decision-making in healthcare settings.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing therapeutics that restore the function of microglia, the brain's immune cells. The company aims to improve outcomes for patients with neurodegenerative diseases by advancing its lead monoclonal antibody TREM2 agonist through Phase 1 trials and progressing its small molecule TREM2 agonist towards an Investigational New Drug (IND) application.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Altis Biosystems, LLC is a biotechnology company specializing in the development of innovative stem cell technologies aimed at enhancing research in human biology. Established in 2015 and based in Chapel Hill, North Carolina, the company has created a patent-pending system known as RepliGut, which effectively recreates the human intestinal epithelium and colonic epithelium. This advanced technology enables the generation of a layer of human or animal intestinal stem and differentiated cells from both the small and large intestines. Altis Biosystems' products are primarily utilized in preclinical studies for disease modeling, precision medicine, microbiome research, and compound screening, serving the needs of pharmaceutical and biotechnology companies. By utilizing normal human intestinal tissue, the company aims to improve drug development processes while minimizing reliance on animal testing.

CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.

Shattuck Labs is a clinical-stage biotechnology company focused on developing therapeutics for cancer and autoimmune diseases. Its proprietary Agonist Redirected Checkpoint (ARC) platform enables the creation of novel fusion proteins with applications in oncology and immunology. The company's lead program, SL-279252, is being studied in Phase I trials for advanced solid tumors and lymphoma, in collaboration with Takeda Pharmaceuticals.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

WalletFi is a subscription management solution tailored for financial institutions and fintech companies. It develops a white-label application that helps users manage their recurring charges effectively. Utilizing machine learning technology, WalletFi's application identifies subscriptions, recurring payments, and Card-on-File merchants. This capability provides users with personalized insights and detailed analytics, allowing financial institutions to enhance customer engagement and wellness. By offering measurable returns on investment, WalletFi empowers its clients to expand their influence within the customer base.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor, intended to manage uncontrolled bleeding events or urgent surgeries. PhaseBio is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, specializing in the development of surgical instruments for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. Founded in 2014, the company has created a series of disposable surgical tools designed to work alongside general-use endoscopic staplers. These innovative tools help surgeons standardize their techniques, reduce variability, and minimize waste during procedures. By decreasing the number of cartridges needed for each surgery, Standard Bariatrics enables healthcare providers to lower costs while ensuring consistent surgical outcomes.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Founded in 2012, Wildflower Health is a San Francisco-based company that specializes in smartphone-based health programs. It offers Due Date Plus for maternity care and GROW for family health, providing services such as reminders, provider look-up, and health risk assessments to support users and connect them with healthcare providers.

NurseGrid is a technology company founded by nurses and entrepreneurs, specializing in streamlining staffing and communication processes within healthcare facilities. They offer two primary products: NurseGrid Mobile and NurseGrid Manager. NurseGrid Mobile empowers over 300,000 registered nurses to manage complex schedules, connect with colleagues, and improve work-life balance via a highly-rated iOS app. Meanwhile, NurseGrid Manager assists nursing departments in simplifying team communication, staffing, and schedule management, complementing core scheduling systems like Kronos and McKesson. This enhances productivity, increases job satisfaction, and aids in nurse retention for healthcare facilities nationwide.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

Rodin Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through epigenetic modulation. Founded in 2013, the company leverages insights into key epigenetic regulators of central nervous system (CNS) function to create innovative treatments. Rodin's approach involves harnessing the power of epigenetic regulation, particularly through the modulation of HDAC complexes, to restore synaptic function and enhance neuronal health in patients suffering from degenerative brain diseases. The company is supported by a team experienced in CNS drug development and has access to advanced structural biology capabilities. Rodin Therapeutics operates as a subsidiary of Alkermes Inc.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

MATI Energy, founded in 2012 and headquartered in Durham, North Carolina, specializes in organic caffeinated energy drinks designed for health-conscious consumers seeking enhanced performance. The company offers a range of no-spike, no-crash beverages that provide a refreshing alternative to traditional energy drinks. These carbonated mixtures focus on delivering a natural boost without compromising on taste or using unhealthy ingredients, catering to individuals who prioritize both vitality and well-being in their daily routines.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Bivarus, Inc. is a Durham, North Carolina-based company that specializes in developing a cloud-based analytics platform aimed at enhancing the patient experience in healthcare settings. Founded in 2010, Bivarus emerged from academic research that established patient experience as a key factor in determining health outcomes. The platform provides healthcare leaders with real-time, actionable insights into factors affecting patient experience, provider performance, and overall service operations. By utilizing a sophisticated sampling algorithm, Bivarus delivers targeted measures to patients, enabling organizations to identify root causes of service issues and track quality improvement initiatives effectively. Additionally, Bivarus is recognized as a CMS-approved CAHPS® partner, offering comprehensive services that include measuring employee perceptions of organizational effectiveness and engagement. As a subsidiary of Press Ganey Holdings, Inc., Bivarus continues to play a pivotal role in transforming how healthcare organizations understand and enhance the patient experience.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Boragen Inc. is a biotechnology company specializing in the design and development of multifunctional small molecule boron solutions for crop protection, animal health, and human health applications. Its pipeline includes products like BAG8, a boron-based multisite fungicide for crops, and BN2266, an innovative MOA crop protection fungicide targeting mRNA processing.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Bivarus, Inc. is a Durham, North Carolina-based company that specializes in developing a cloud-based analytics platform aimed at enhancing the patient experience in healthcare settings. Founded in 2010, Bivarus emerged from academic research that established patient experience as a key factor in determining health outcomes. The platform provides healthcare leaders with real-time, actionable insights into factors affecting patient experience, provider performance, and overall service operations. By utilizing a sophisticated sampling algorithm, Bivarus delivers targeted measures to patients, enabling organizations to identify root causes of service issues and track quality improvement initiatives effectively. Additionally, Bivarus is recognized as a CMS-approved CAHPS® partner, offering comprehensive services that include measuring employee perceptions of organizational effectiveness and engagement. As a subsidiary of Press Ganey Holdings, Inc., Bivarus continues to play a pivotal role in transforming how healthcare organizations understand and enhance the patient experience.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Medfusion, Inc. is a healthcare technology company based in Cary, North Carolina, specializing in patient engagement solutions that enhance communication between healthcare providers and patients. Founded in 1996, Medfusion offers a comprehensive patient engagement portal that encompasses clinical, administrative, and financial services. Its solutions include billing options such as online payments and payment plans, clinical tools for secure messaging and prescription requests, and front desk functionalities like appointment scheduling and patient registration. The company also provides mobile applications to facilitate patient access to health data and payment processing. Additionally, Medfusion's Practice Intelligence service assists healthcare practices in managing patient communication traffic effectively. By focusing on improving the patient experience and operational efficiency, Medfusion aims to support healthcare providers in delivering better services while also generating revenue.

Founded in 2012, Wildflower Health is a San Francisco-based company that specializes in smartphone-based health programs. It offers Due Date Plus for maternity care and GROW for family health, providing services such as reminders, provider look-up, and health risk assessments to support users and connect them with healthcare providers.

NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, that focuses on developing innovative products for metabolic diseases linked to over-nutrition, such as obesity and diabetes. Established in 2007, the company has created a technology platform that combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to prevent and treat chronic conditions associated with aging. Its flagship product, NS-0100, combines the natural compound leucine with a low dose of metformin to address type 2 diabetes, particularly for patients who experience gastrointestinal side effects from standard metformin treatment. NuSirt is currently conducting Phase 2 clinical trials to determine the optimal dosage of NS-0100. The company has filed eleven patent applications related to its technologies, with two patents already issued, and has successfully completed four clinical studies alongside various pre-clinical investigations.

Founded in 2013, Spyryx Biosciences is a biopharmaceutical company dedicated to developing inhaled peptide therapeutics for obstructive lung diseases. Its primary focus is on cystic fibrosis and chronic obstructive pulmonary disease (COPD). The company's innovative approach aims to address the root causes of these conditions by targeting mechanisms that regulate fluid in the lungs.

Contego Medical is a medical device company that develops integrated embolic protection technologies for cardiovascular and endovascular procedures. Its product line includes angioplasty balloons and stent delivery catheters that combine treatment and embolic protection, enabling safer interventions in carotid, renal, SVG, and coronary arteries. The company holds FDA clearance for the Paladin Carotid PTA Balloon System with Integrated Embolic Protection, the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection, and the Excipio SV Thrombectomy Device. Founded in 2005, Contego Medical is headquartered in Raleigh, North Carolina, with an additional office in Curitiba, Brazil.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor, intended to manage uncontrolled bleeding events or urgent surgeries. PhaseBio is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.

Clinverse is a technology company that specializes in the financial management of clinical trials and related payments across more than 140 currencies. Its primary offering, ClinPay, is an online eClinical Trial Payment Network designed to enhance the efficiency of the investigator payment process. By connecting sponsors directly with investigators, ClinPay streamlines payment and reporting, leading to reduced study start-up times and improved accuracy in payments. The platform also provides essential features such as transparency, comprehensive auditing records, and simplified compliance, all of which contribute to increased productivity in clinical trials.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Jumo Health is a New York-based company founded in 2009 that specializes in developing age-appropriate and culturally sensitive educational resources for patients and caregivers. The company collaborates with healthcare providers, manufacturers, and advocacy groups to deliver these resources at critical points in the medical journey, including diagnosis, treatment, and clinical trials. Jumo Health focuses on simplifying complex medical topics through engaging mediums such as comic books, animation, virtual reality experiences, and documentary-style patient stories. By employing visual elements and familiar formats, Jumo Health aims to enhance understanding and accessibility of evidence-based medical literature for diverse audiences.

Curoverse, Inc. is a Boston-based company that develops and operates a cloud-based open-source platform named Arvados, which focuses on the storage, organization, analysis, and sharing of genomic and biomedical data. Originally incorporated in 2010 as Clinical Future, Inc., the company rebranded in December 2013. Curoverse employs open-source software to provide management and computational services tailored to the unique needs of genomic data, empowering scientists and clinicians to facilitate breakthrough discoveries and enhance patient care. The Arvados platform allows for secure access to patient-level genomic and health data, supporting drug development and precision medicine by enabling the management, processing, analysis, and sharing of extensive biomedical data sets, including genomics and imaging.

Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.